Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions.

McGinley, Marisa P; Cohen, Jeffrey A

McGinley, Marisa P; Cohen, Jeffrey A.

Affiliation

McGinley MP; Mellen Center, Cleveland Clinic, Cleveland, OH, USA.
Cohen JA; Mellen Center, Cleveland Clinic, Cleveland, OH, USA. Electronic address: cohenj@ccf.org.

Lancet ; 398(10306): 1184-1194, 2021 09 25.

Article in En | MEDLINE | ID: mdl-34175020

Subject(s)

Clinical Trials as Topic; Multiple Sclerosis/drug therapy; Sphingosine 1 Phosphate Receptor Modulators/pharmacology; Sphingosine 1 Phosphate Receptor Modulators/therapeutic use; Sphingosine-1-Phosphate Receptors; Animals; Azetidines/pharmacology; Azetidines/therapeutic use; Benzyl Compounds/pharmacology; Benzyl Compounds/therapeutic use; Fingolimod Hydrochloride/pharmacology; Fingolimod Hydrochloride/therapeutic use; Humans; Immune System Diseases/drug therapy; Indans/pharmacology; Indans/therapeutic use; Nervous System Diseases/drug therapy; Oxadiazoles/pharmacology; Oxadiazoles/therapeutic use; Signal Transduction/drug effects; Sphingosine 1 Phosphate Receptor Modulators/classification; Thiazoles/pharmacology; Thiazoles/therapeutic use

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Clinical Trials as Topic / Sphingosine 1 Phosphate Receptor Modulators / Sphingosine-1-Phosphate Receptors / Multiple Sclerosis Limits: Animals / Humans Language: En Journal: Lancet Year: 2021 Document type: Article

Fulltext

XML

PubMed Links

Search on Google